NASDAQ:IRWD - Ironwood Pharmaceuticals Stock Price, Price Target & More

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) posted its quarterly earnings results on Tuesday, May, 1st. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.06. The biotechnology company had revenue of $69.16 million for the quarter, compared to analysts' expectations of $78.65 million. Ironwood Pharmaceuticals had a negative return on equity of 2,073.20% and a negative net margin of 34.12%. The firm's revenue was up 32.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.33) EPS. View Ironwood Pharmaceuticals' Earnings History.

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Ironwood Pharmaceuticals.

9 Wall Street analysts have issued twelve-month target prices for Ironwood Pharmaceuticals' shares. Their forecasts range from $13.00 to $25.00. On average, they anticipate Ironwood Pharmaceuticals' stock price to reach $19.4444 in the next twelve months. View Analyst Ratings for Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals saw a drop in short interest in May. As of May 15th, there was short interest totalling 18,814,070 shares, a drop of 12.2% from the April 30th total of 21,438,253 shares. Based on an average daily trading volume, of 1,695,797 shares, the days-to-cover ratio is presently 11.1 days. Currently, 13.7% of the company's shares are short sold. View Ironwood Pharmaceuticals' Current Options Chain.

Some companies that are related to Ironwood Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Nektar Therapeutics (NKTR), BeiGene (BGNE), Genmab A/S (GNMSF), Valeant Pharmaceuticals Intl (VRX), Alkermes (ALKS), SAGE Therapeutics (SAGE), Sarepta Therapeutics (SRPT), Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT), Ionis Pharmaceuticals (IONS) and Loxo Oncology (LOXO).

Media stories about IRWD stock have trended somewhat positive on Wednesday, Accern reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ironwood Pharmaceuticals earned a news sentiment score of 0.04 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 44.89 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Ironwood Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BVF Inc. IL (3.65%), OppenheimerFunds Inc. (1.70%), Northern Trust Corp (1.03%), Loomis Sayles & Co. L P (1.01%), Sector Gamma AS (0.74%) and Schwab Charles Investment Management Inc. (0.45%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

IRWD stock was sold by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, Artal Group S.A., State of Wisconsin Investment Board, Barclays PLC, Sector Gamma AS, Loomis Sayles & Co. L P, California Public Employees Retirement System and Russell Investments Group Ltd.. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Mark G Currie and Peter M Hecht. View Insider Buying and Selling for Ironwood Pharmaceuticals.

IRWD stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, OppenheimerFunds Inc., UBS Group AG, Engineers Gate Manager LP, Point72 Asset Management L.P., Trexquant Investment LP, Schwab Charles Investment Management Inc. and Alps Advisors Inc.. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IRWD stock can currently be purchased for approximately $18.60.

Ironwood Pharmaceuticals has a market capitalization of $2.82 billion and generates $298.28 million in revenue each year. The biotechnology company earns $-116,930,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Ironwood Pharmaceuticals employs 730 workers across the globe.

Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]